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CRN2 (synonyms: coronin 1C, coronin 3) functions in the re-organization of the actin network and is
implicated in cellular processes like protrusion formation, secretion, migration and invasion. We
demonstrate that CRN2 is a binding partner and substrate of protein kinase CK2, which phosphorylates
CRN2 at S463 in its C-terminal coiled coil domain. Phosphomimetic S463DCRN2 loses thewild-typeCRN2
ability to inhibit actin polymerization, to bundle F-actin, and to bind to the Arp2/3 complex. As a
consequence, S463D mutant CRN2 changes the morphology of the F-actin network in the front of
lamellipodia. Our data imply that CK2-dependent phosphorylation of CRN2 is involved in the modulation
of the local morphology of complex actin structures and thereby inhibits cell migration.
C
oronins play an essential role in the structural and functional organization of actin-dependent cellular
processes like protrusion formation, secretion, migration, and invasion. Phylogenetic analyses have
revealed twelve subfamilies of coronin proteins, consisting of seven vertebrate paralogs and five subfam-
ilies in non-vertebrate metazoa, fungi, and protozoa1. Coronins are structured with a rather short, conserved,
basic N-terminal signature motif, followed by one, or, in case of the coronin 7 ‘dimer’ subfamily, two 7-repeat
WD40 domains which adopt the fold of a seven-bladed b-propeller. A unique C-terminal extension links the
WD40 repeat domains with the C-terminal coiled coil domain2,3.
The predominant form of CRN2 is isoform 1 (CRN2i1), a ubiquitously expressed 474 amino acid protein4,5.
CRN2 forms homotrimers via the coiled coil domain and has been identified as an actin filament cross-linking
and bundling protein4,6. It exists in two different pools, an actin cytoskeleton associated non-phosphorylated pool
enriched at lamellipodia and a diffusely distributed phosphorylated cytosolic pool, however, the phosphorylation
site and the kinase are unknown4. In themurine brain, CRN2 seems to play a role inmorphogenesis and in certain
neuronal cell populations in the adult animal7. Recently, CRN2 has also been implicated in human cancer. While
normal resting astrocytes do not express CRN2, the number of CRN2-positive tumor cells is correlated with the
malignant phenotype in human diffuse gliomas. Knock-down of CRN2 in human glioblastoma cell lines reduces
the rate of cell proliferation, motility, and invasion8. Furthermore, CRN2 is aberrantly regulated in melanoma
with an increase of CRN2 expression in metastatic tumor cells9. In hepatocellular carcinoma, CRN2 expression
levels correlates with clinical progression10. In a recent analysis of primary effusion lymphoma specimens, the
CRN2 genewas found to be amplified in one-fourth of the specimens andCRN2 expression levels were elevated in
three-fourths of the specimens11. However, a different effect was observed in another study, where a knock-down
of CRN2 in colon carcinoma cell lines appeared to induce opposite effects like enhanced cell migration and the
increased number of focal adhesions12.
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Several reports support a role for CRN2 in signaling pathways that
involve small G-proteins. A short sequence stretch that resembles the
Cdc42/Rac interactive binding (CRIB) motif is present in CRN2 and
could act as a potential binding site for the activated GTP-binding
proteins Rac and Cdc42 involved in the regulation of the actin cytos-
keleton13. CRN2 has also been found to be a direct binding partner of
GDP-Rab27a. GDP-Rab27a was found to increase the F-actin bund-
ling activity of CRN2 and the protein complex was shown to be
involved in the insulin secretory membrane endocytosis14,15.
In this study, we demonstrate that CRN2 function is regulated by
CK2-dependent phosphorylation. Protein kinase CK2 (synonyms:
casein kinase II, CK II) was first described in a mixture with CK1
using casein as an artificial substrate16. It is an evolutionarily highly
conserved, ubiquitously expressed, highly pleiotropic, and constitu-
tively active serine and threonine kinase17,18,19,20,21,22. CK2 is involved
in the control of a wide variety of cellular functions including tran-
scription, translation, cell cycle, signal transduction, apoptosis, meta-
bolism, virus infection, cell morphology, malignant transformation,
and tumor development23,24,25. CK2 primarily exists as a heterotetra-
meric protein of either 2a2b, 1a1a’2b or 2a’2b subunit composi-
tion26,27,28,29,30. In these CK2 complexes, the two regulatory subunits
CK2b form a stable dimer linking together the two catalytic subunits,
CK2a or CK2a’29.
We show here that a CK2-dependent phosphorylation of CRN2 at
residue S463 leads to a loss of CRN2-mediated inhibition of actin
polymerization as well as to a loss of its F-actin bundling activity and
Arp2/3 complex interaction. Together, these changes affect the archi-
tecture of the F-actin network and result in an inhibition of cell
migration. Furthermore, this work reveals that bundling of actin
filaments occurs via two separate actin binding sites in CRN2 and
that the CRN2 coiled coil domain forms a constitutive trimer which
either can interact with F-actin or the Arp2/3 complex.
Results
Identification of Ser at position 463 as a specificity determining
site in the mammalian and avian CRN2 subfamily. An alignment
of 40 mammalian and avian proteins out of a subclassification of 60
orthologs used in previous phylogenetic analyses of coronin family
homologs1 was first transformed into a profile hiddenMarkovmodel
(pHMM) using the HMMER implementations in Unipro-Ugene
(http://ugene.unipro.ru/) and visualized with LogoMat-M (http://
www.sanger.ac.uk/Software/analysis/logomat-m/). This identified
evolutionarily conserved amino acid patterns with the highest
probabilities of information content or functional significance.
‘‘Specificity determining positions’’ (SDPs) peculiar to the CRN2
subfamily were identified by SDPclust31, SDPfox (http://bioinf.fbb.
msu.ru/SDPfoxWeb/main.jsp), and ‘‘type II divergence’’32 among
300 coronins representing all seven subfamily groups present
in mammals and birds and were marked with an asterisk in the
corresponding position of the pHMM sequence logo for CRN2
(Fig. 1A). The concentration of these SDP sites in the N- and C-
terminal domains argues for a predominant role of these regions
in the functional differentiation of coronin subfamilies. Other
highlighted sites, which are known to be susceptible to post-trans-
lational modifications, included Tyr-30133,34 and acetylated lysines
391 and 44635 in CRN2 and various other coronin subfamilies. In
contrast, the incorporation of Ser at position 463 was confined to the
CRN2 subfamily. The emergence and restricted conservation of S463
may thus reflect the selection for a structural and functional feature
that allows for the regulation of CRN2 subcellular interactions
through phosphorylation. A putative functional role of S463 is fur-
ther emphasized by its localization within the coiled coil domain of
CRN2 known to be responsible for CRN2 homo-trimerization4. A
homology model of the trimeric CRN2 coiled coil domain (aa442-
472) based on the crystal structure of the trimeric coiled coil of
hemagglutinin36 indicated that S463 is surface exposed (Fig. 1B).
Figure 1 | Phosphorylation of S463 within the CRN2 coiled coil does not
induce trimer disassembly. (A) profile hidden Markov model (pHMM)
of the CRN2 subfamily. The probability distribution of amino acids within
the CRN2 subfamily is reflected by letter height while the ‘‘functional
significance’’ predicted by HMMER is given by the full column height at
each site. The Ser-463 phosphorylation site is uniquely conserved within the
CRN2 subfamily, whereas sites of other predicted post-translational changes
(P-Tyr-301, Ac-Lys-391 and Ac-Lys-446) are common to a limited number
of other coronin subfamilies. Asterisks mark amino acids identified by
SDPfox which show evidence of a conservation pattern able to distinguish
individual coronin subfamilies and are therefore taken to confer ‘‘functional
specificity’’. These SDPs localized mainly to regions of the N- and C-
terminal domains, in contrast to the ‘‘KGD’’ motif universally conserved in
coronin proteins (aa485-487 in CRN2). (B) homology model of the trimeric
CRN2 coiled coil (aa442-447, monomer chains A, B, C) based on the crystal
structure of the trimeric coiled coil of hemagglutinin (HA2 chain) using
residues 74 to 113 from chain B (36; PDB 1eo8). Interactions of
phosphorylated S463 (pS463, see C) with R461 and K464 are illustrated. (C)
size-exclusion chromatogram of synthetic pS463-CRN2 peptide (18 mg/ml)
acquired on a Superose-12 column under normal (100 mM) and high salt
(500 mM NaCl) conditions. The peptide eluted as single species whose
molecular mass was determined using the online multi-angle light scattering
(MALS) detector; theoretical mass of the trimer is 13,959 g/mol.
www.nature.com/scientificreports
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The location of S463 in a solvent accessible a-helical surface seg-
ment also is visualized in a three-dimensional refined model of the
human CRN2 protein predicted by I-Tasser37 and rendered with
Chimera v1.538 (Fig. S1). Finally, it is important to note that S463
is part of the sequencemotif S-K-L-E coinciding with the S/T-X-X-E/
D consensus target motif of the protein kinase CK2.
Phosphorylation of S463 does not induce disassembly of the
CRN2 trimer. To address the issue of trimer stability at the
experimental level, gel filtration experiments in conjunction with
multi-angle light scattering detection (SEC-MALS) were carried
out to determine the oligomerization state of synthetic wild-type
and phospho-S463 CRN2 coiled coil peptides (aa442-472; 3.7 kDa).
Under physiological buffer conditions, the S463 phosphorylated
synthetic CRN2 peptide eluted as trimer (Fig. 1C). Furthermore,
small-angle X-ray scattering (SAXS) was conducted in solution
and also showed the presence of a trimeric particle, independent of
the concentration of the sample. The molecular mass and radius of
gyration derived from the SAXS experiments were in good agree-
ment with the expected values from the atomic homology model
(Tab. S1). The shape restored from the X-ray scattering data in
solution was fitted with the atomic homology model of the tri-
meric coiled coil as rigid body and revealed an excellent agreement
(Fig. S2). The goodness of fit between the experimental and theoretical
scattering curves was calculated by CRYSOL39 as x 5 5.5. Additional
gel filtration analyses were carried out using purified recombinant
wild-type, S463D phosphomimetic and S463A phospho-resistant C-
terminal polypeptides (aa300-474; 19.9 kDa), full-length wild-type
and S463D phosphomimetic proteins purified from insect cells
(53.2 kDa), and lysates of mammalian cells over-expressing GFP-
fusion proteins of wild-type, S463D and S463A CRN2. These ex-
periments clearly demonstrate a strong CRN2 trimer that is not
disassembled by S463 phosphorylation. With ,40 nM the concen-
trations of full-length CRN2 were far lower than the lowest
concentration (4.5 mg/ml o 1.2 mM) used for of the synthetic
peptides and the protein could only be detected by immunoblotting.
CRN2directly interacts with protein kinase CK2. Since our in silico
analysis indicated that CRN2 S463 is part of a consensus CK2 target
motif, an interaction between the CK2a catalytic subunit and CRN2
was tested by pull-down assays. Experiments employing purified
GST-tagged CK2a coupled to glutathione beads as bait and
purified soluble CRN2 wild-type or phosphomimetic S463D
mutant C-terminal polypeptides as prey showed an interaction
between both CRN2 variants and CK2a (Fig. 2A). The experiment
was repeated with endogenous as well as GFP-tagged full-length
CRN2 proteins from HEK293 cell lysates and showed identical
results (Fig. 2B). In both experiments CRN2 also interacted with a
dead kinase K68A mutant of CK2a40.
S463 within the CRN2 coiled coil domain is phosphorylated by
CK2a. We performed in vitro kinase assays to address the question
whether the interaction between CK2a and CRN2 leads to phos-
phorylation of CRN2. When the wild-type CRN2 C-terminal
polypeptide was incubated with CK2a, a CRN2 phosphorylation
signal was detected which increased with the incubation time
(Fig. 3A). In contrast, the incubation of the S463D mutant resulted
in very low levels of phosphate incorporation from [c-32P]ATP.
In addition, kinase assays were performed with recombinant full-
length CRN2 proteins purified from insect cells. Wild-type full-
length CRN2 was also phosphorylated in a time dependent
manner (Fig. 3B). In case of the S463D mutant, phosphorylation
signals were hardly detectable at 30 min, and did not reach the
intensity of wild-type CRN2 after an extended incubation time of
120 min. These experiments demonstrate that S463 is phospho-
rylated by CK2a.
CK2 contributes to the pool of phosphorylated CRN2 in vivo.We
performed de-phosphorylation experiments to verify the presence of
phosphorylated CRN2 within the cell. Lysates from samples of
murine tissues were incubated with alkaline phosphatase and
Figure 2 | CRN2 directly interacts with CK2a. (A) pull-down assay
employing purified recombinant full-length GST-tagged CK2a coupled
to glutathione beads and purified soluble CRN2 wild-type and
phosphomimetic S463D C-terminal polypeptides (aa300-474). Both
polypeptides bind to CK2a and CK2adead, the latter lacks kinase activity.
(B) pull-down assay employing purified recombinant full-length GST-
tagged CK2a coupled to glutathione beads and lysates from HEK293 cells
over-expressing endogenous CRN2 (57 kDa) as well as GFP-CRN2
(82 kDa) fusion proteins. Endogenous, wild-type GFP-CRN2, and GFP-
CRN2 S463D bind to CK2a. All CRN2 polypeptides were detected with
antibody K6-444, and GST-CK2a immunoblotting was done with a rabbit
polyclonal GST-antibody86. Asterisk, two additional CK2a bands are the
result of degradation. Controls contained beads coated with GST alone.
For illustration purposes individual lines from the original western blots
were digitally re-arranged.
www.nature.com/scientificreports
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analyzed by two-dimensional gel electrophoresis in conjunction with
CRN2 immunoblotting. A single spot of CRN2 was detected in
untreated samples of skeletal muscle tissue. This spot shifted to a
more alkaline pI after treatment with alkaline phosphatase. The
distance between both spots was approximately 0.5 pH units and
corresponded to a calculated loss of three phosphate residues. Si-
milar results, however with the presence of multiple spots, were
obtained for murine brain tissue (Fig. 4A).
In a next step, we confirmed that phosphorylation of CRN2 also
occurs in aCK2-dependentmanner in vivo. 293TN cells over-expres-
sing GFP-CRN2 were grown in the presence of the CK2 inhibitor
TBB, the CK2 activator 1-ethyl-4,5-dicarbamoylimidazole41,42,43 or
solvent control before addition of 32P-orthophosphate. We deter-
mined a 40% reduction of CRN2 phosphorylation in case of the
CK2 inhibitor and an 80% increase in case of the CK2 activator
strongly supporting a physiologically relevant CK2 dependent phos-
phorylation of CRN2 in vivo (Fig. 4B). Since it has been reported that
S13 phosphorylation of theHsp90 co-chaperone cdc37 is amarker of
Figure 4 | CK2 phosphorylates CRN2 in vivo. (A) presence of a
phosphorylated pool of endogenous CRN2. Lysates of murine skeletal
muscle (upper three panels) and brain tissue (lower two panels) were
separated by 2D-gel electrophoresis. CRN2 was visualized by western
blotting using mAb K6-444. The first panel presents the untreated sample
(ctrl), the second panel the in vitro de-phosphorylated sample (alkaline
phosphatase, AP), and the third panel shows two CRN2 spots resulting
from a mixture of the untreated and de-phosphorylated samples (muscle
sample only). In contrast to brain tissue (forth and fifth panel), in skeletal
muscle only a single spot of CRN2 is detected which corresponds to CRN2
isoform 35. (B) modulation of the in vivo CK2 activity changes the
phosphorylation status of CRN2. 293TN cells over-expressing GFP-CRN2
were grown in the presence of the CK2 inhibitor TBB, the CK2 activator
1-ethyl-4,5-dicarbamoylimidazole or solvent control before addition of
32P-orthophosphate. Subsequently, cells were lysed, GFP-CRN2 was
immunoprecipitated, samples were separated by SDS-PAGE, proteins
were stained by Coomassie brilliant blue (first panel), and gels were dried
and used for autoradiography (second panel). Densitometric analysis
determined that the CK2 inhibitor decreased the level of CRN2
phosphorylation by 40%, while application of the activator led to an
increase of 80% (third panel). Immunoblots for pS13-cdc37, a marker of
the in vivo CK2 activity, total cdc37, and CK2a are given as controls (forth
to sixth panel). One representative experiment is shown. First and second
panel, for illustration purposes the order of lines from the original data was
digitally re-arranged. Asterisk, unspecific autoradiography signal which
does not correspond to the Coomassie stained CRN2 protein band.
Figure 3 | CRN2 is a target of CK2a and is phosphorylated at S463.
(A) in vitro kinase assays employing recombinant full-length GST-CK2a
(66 kDa, arrow) and His-tagged C-terminal polypeptides of CRN2
(30 kDa, arrowheads). Time course (30, 60, 90 minutes) of phosphate
incorporation from [c-32P]ATP into wild-type as well as S463D mutant
CRN2 polypeptides. Controls where the CRN2 polypeptide, [c-32P]ATP,
or CK2awere omitted and use of a kinase-dead CK2a are indicated. Upper
panel, autoradiograph of phosphorylation of CRN2 (32P). Lower panel, the
corresponding Coomassie brilliant blue stained gel. For all lines containing
CK2a identical volumes from the same preparation of purified enzyme
were used. Molar concentrations, CK2a 30 nM, CRN2 1.8 mM. Asterisk,
contamination by the E. coli 70 kDa chaperone DnaK. Wild-type CRN2
is phosphorylated in a time-dependent manner. Note the minor
phosphorylation levels of themutant polypeptide after 90 min. (B) in vitro
kinase assay employing recombinant full-length GST-CK2a (66 kDa,
arrow) and GST-His-tagged full-length CRN2 purified from insect cells
(90 kDa, arrowheads). Time course (1, 5, 10, 30 minutes) of phosphate
incorporation from [c-32P]ATP into wild-type CRN2. Controls where
CRN2, [c-32P]ATP, or CK2a were omitted and use of a kinase-dead CK2a
are indicated. Upper panel, autoradiograph of phosphorylation of CRN2
(32P). Lower panel, the corresponding Coomassie brilliant blue stained gel.
For all lines containing CK2a identical volumes from the same preparation
of purified enzyme were used. CRN2 is phosphorylated in a time-
dependentmanner. Note, that only after longer incubation time (120 min)
the phosphorylation level of S463Dmutant CRN2 reaches the one of wild-
type CRN2.
www.nature.com/scientificreports
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in vivo CK2 activity44,45, blots were probed for pS13-cdc37, total
cdc37, and CK2a for control. We observed a complete suppression
of cdc37 phosphorylation in presence of TBB while the levels of
cdc37 and CK2 proteins remained unchanged (Fig. 4B, bottom
panel). The pattern of an effective TBB induced suppression of
cdc37 phosphorylation and an effective 1-ethyl-4,5-dicarbamoylimi-
dazole induced stimulation of CRN2 phosphorylation suggests less
CK2-dependent phosphorylation of CRN2 under basal cellular
conditions.
CRN2 and CK2 co-localize at the front of lamellipodia. Im-
munofluorescence analyses were carried out in lamellipodia-rich
Pop10 cells to determine the subcellular distribution of CK2
relative to CRN2 and F-actin. Previous studies have shown that the
subcellular localization of CRN2 does not change upon CRN2 over-
expression6 and that the amount of F-actin is not influenced by the
level of CRN2 expression8. In Pop10 cells over-expressing GFP-
CRN2 fusion proteins, CRN2 and CK2 were enriched and co-
localized in the perinuclear region (Fig. 5, arrowheads) and at the
front of lamellipodial structures (Fig. 5, arrows). Lamellipodia
showed a co-localization of CRN2, CK2, and F-actin. F-actin stress
fibers, which were co-stained by CRN2, did not show any overt
enrichment of CK2 (Fig. 5, double-arrowheads). No differences in
these patterns were detected, when the cells over-expressed phospho-
mimetic S463D or phospho-resistant S463A CRN2 instead of the
wild-type protein.
Wild-type but not S463D phosphomimetic CRN2 inhibits actin
polymerization.An influence of CRN2 on actin polymerization was
determined in actin polymerization experiments employing G-actin
and the Arp2/3 complex together with its activator, the VCA domain
of N-WASP. Wild-type CRN2 and the S463A mutant, but not the
phosphomimetic S463D CRN2 C-terminal polypeptide, effectively
inhibited actin polymerization. CRN2 reduced the velocity of actin
filament growth (Fig. 6A; slopes decreased) and the final amount of
F-actin (Fig. 6A; plateaus decreased). This inhibitory effect of CRN2
was apparent in the presence or absence of Arp2/3 complex and
VCA, although the CRN2 mediated inhibition of actin polymeri-
zation always could be antagonized to a limited extent by addition
of the Arp2/3 complex (Fig. 6B).
To verify the specificity of these assays, the CRN2 polypeptides
were added to pre-polymerized actin. Here, a small and identical
quenching effect of the fluorescence signal of F-actin was observed
with every polypeptide tested. It is noteworthy, that the inhibitory
effect of CRN2 on actin polymerization was dose-dependent. Low
starting concentrations of CRN2 C-terminal polypeptides caused
only decreasing velocities of actin polymerization, whereas the high-
est CRN2 concentration (but lower than the one used in Fig. 6A)
additionally reduced the final amount of F-actin (Fig. 6C). A dose-
dependent effect was only detected for the wild-type and S463A
mutant CRN2 polypeptides, while the phosphomimetic S463D
CRN2 C-terminal polypeptide did not show such an effect (Fig. 6D).
However, high S463D CRN2 to actin ratios (see figure legend) as used
in the experiments shown in Fig. 6A caused a partial inhibition of actin
polymerization.
To address the possibility that the inhibitory effect of CRN2 on
actin polymerization might result from sequestration of G-actin, we
performed fluorescence-based G-actin binding assays. Here, a
change in the fluorescence signal of G-actin upon binding of a test
protein was only detected for the WH2-domain of CAP2 as control,
but not for any of the CRN2 polypeptides. A potential capping effect
of CRN2 thatmight reduce actin polymerization can be excluded due
to the high molar ratio of CRN2 vs. G-actin in these assays (see
Materials and Methods).
Phosphorylation of CRN2 at S463 affects its interaction with
F-actin and Arp2/3 complex. Two-step F-actin co-sedimentation
assays were employed to study the interactions of the CRN2 C-
terminal polypeptides with F-actin. Wild-type and S463A mutant
CRN2 induced the formation of F-actin bundles (Fig. 7A, 10,000xg
first pellet), with less binding and co-sedimentation with actin fila-
ments (100,000xg second pellet). S463D phosphomimetic CRN2
demonstrated opposite effects with enrichment in the 100,000xg
actin filament pellet and markedly reduced F-actin bundling
activity (10,000xg pellet). Addition of Arp2/3 did not change these
patterns. However, the CRN2 C-terminal polypeptides competed
with the Arp2/3 complex for F-actin binding. Arp2/3 immunoblots
of samples derived from 100,000xg F-actin co-sedimentation assays
indicated a partial release of theArp2/3 complex into the supernatant
upon the addition of either wild-type or mutant CRN2 polypeptides
(Fig. 7B). The interaction of the CRN2 polypeptides as well as of full-
length wild-type, S463D and S463A mutant CRN2 proteins with the
Arp2/3 complex was further studied by pull-down and co-immu-
noprecipitation experiments. Both, wild-type and S463A mutant
CRN2 bound directly to the Arp2/3 complex, while phospho-
mimetic S463D CRN2 showed essentially no binding (Fig. 7C,D,E).
Phosphomimetic S463D CRN2 changes the architecture of the F-
actin network in the front of lamellipodia and inhibits cell
migration. To demonstrate a functional role of CRN2 phospho-
rylation at S463, U373 human glioblastoma cells with a stable
shRNA-mediated knock-down of endogenous CRN2 were trans-
fected with GFP-tagged, shRNA resistant wild-type, phosphomi-
metic S463D or phospho-resistant S463A mutant CRN2 expression
constructs. Replacement of the endogenous CRN2 by the S463A
mutant CRN2 led to cells with a smooth and regular co-distribution
of CRN2, F-actin, and Arp2/3 complex at the lamellipodia (Fig. 8A).
In contrast, cable-like enrichments of CRN2 and F-actin and a
disrupted distribution of the Arp2/3 complex were detected in the
front of lamellipodial extensions in case of the S463D mutant
(Fig. 8B). Furthermore, the latter cells showed a thinner region of
CRN2 and Arp2/3 complex (p34-Arc antibody) co-localization,
which was restricted to the very tip of lamellipodia (Fig. 8A,B, right
panels, distance labels). Cells that expressed GFP-tagged wild-type
Figure 5 | CRN2, CK2, and F-actin co-localize in the front of lamellipodia. Pop10 cells over-expressing GFP-tagged CRN2 were fixed and CK2a was
immunolabeled with primary antibody 1AD9 followed by Alexa-633 labeled secondary antibody; F-actin and nuclei were visualized by TRITC-phalloidin
and DAPI, respectively. CRN2 and CK2 co-localize in the peri-nuclear region (arrowheads); CRN2, CK2, and F-actin co-localize in the front of
lamellipodia (arrows). Double-arrowheads, F-actin fibers decorated by CRN2.
www.nature.com/scientificreports
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CRN2 displayed a combination of both phenotypes; a statistical
analysis is given in Fig. S3. The sole reduction of the CRN2 ex-
pression level in U373 cells did not affect the morphology of lamel-
lipodia (see Fig. 3 in reference8).
In order to evaluate if these lamellipodial alterations lead to
changes in cell migration we monitored the formation of cellular
protrusions of HEK293 cells stably expressing the GFP-tagged
CRN2 variants. Compared to the wild-type and S463A mutant
CRN2 situation, the expression of S463D phosphomimetic CRN2
led to a reduction in the number of cellular protrusions by a factor
of two (Fig. 9A). In addition, confluent monolayers of HEK293 cells
were used for in vitro wound healing assays. A reduced velocity in
wound closure was detected in case of S463D phosphomimetic
CRN2 (23 mm/h), compared to wild-type (29 mm/h) and S463A
CRN2 (28 mm/h) expressing cells (Fig. 9B).
S463D CRN2 displays a delayed integration into the podosome
core structure. Alterations in the molecular composition of
podosomes, which are prominent adhesion and invasion structures
that play an important role in the migration of macrophages and
other cell types, further illustrate the cellular relevance of CRN2 S463
phosphorylation. Expression of GFP-CRN2 constructs in primary
human macrophages demonstrated an enrichment of wild-type,
S463D and S463A mutant CRN2 at podosomes, and all three
CRN2 species co-localized with the F-actin core structure (Fig.
S4A-C, ctrl). Various podosomal parameters were investigated in
Figure 6 | Phosphorylation of serine residue 463 controls the inhibitory effect of CRN2 on actin polymerization. (A) CRN2 wild-type and S643A
mutant but not phosphomimetic S463D C-terminal polypeptides effectively inhibit actin polymerization in the presence of Arp2/3 complex. CRN2
reduces the actin polymerization velocity as well as the final amount of F-actin. In this assay a molar ratio of CRN2:actin of 251 was used in order to
enhance the effects and visualize differences between the CRN2 polypeptides. For details of the experimental setup see Materials and Methods section.
RFU, relative fluorescent units. (B) CRN2 C-terminal polypeptides and the Arp2/3 complex exhibit opposite effects on actin polymerization. The
addition of Arp2/3 complex (together with VCA) partially antagonizes the inhibitory effect of CRN2 and increases the actin polymerization velocity. In
this assay a molar ratio of CRN2:actin of 152 was used. (C) CRN2 shows a dose-dependent inhibitory effect on actin polymerization. Increasing
concentrations of wild-type CRN2C-terminal polypeptide only decrease the actin polymerization velocity at first (best visible at the time point of 5 min).
At the highest CRN2 concentration used the final amount of F-actin also is reduced. In this assay the molar ratio of CRN2:actin was 154 to 2.551. (D)
CRN2 wild-type and S463A mutant but not phosphomimetic S463D C-terminal polypeptides affect actin polymerization (in absence of Arp2/3) in a
dose-dependent manner. S463Dmutant CRN2 neither reduces the actin polymerization velocity nor the final amount of F-actin. In this assay the molar
ratio of CRN2:actin was 154 to 1.2551.
www.nature.com/scientificreports
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the transfected macrophages. Determination of the number, mor-
phology, size, subcellular distribution, and F-actin content of podo-
somes revealed no differences with respect to the three different
CRN2 constructs. Also, a nearly complete knock-down of the
endogenous CRN2 demonstrated that podosomes are assembled
independently of CRN2 (Fig. S5). However, when the podosomes
were disrupted by treatment with the Src family kinase inhibitor PP2
and allowed to re-form after washout of the inhibitor, the phospho-
resistant S463A mutant CRN2 was in most cases excluded from the
re-assembled podosomes (Fig. S4C, re-formation; Fig. S6). Further,
fluorescence recovery after photobleaching (FRAP) experiments
were carried out and showed that CRN2 is a fully mobile com-
ponent (plateau after recovery approximately reaches pre-bleach
intensity) of the podosomal structure (Fig. S7, left graphs). An
analysis of the fluorescence recovery via bi-exponential equation
resulted in fitted curves which indicated a significantly reduced koff
value of 0.11 s21 for S463D mutant CRN2 compared to 0.31 s21 and
0.25 s21 for wild-type and S463A mutant CRN2, respectively (Fig. 9C).
The dissociation constants were used for the calculation of the half-life
times which accordingly showed an elevated half life time (t1/2) of 6.56 s
for the S463D mutant in contrast to half-life times of 2.27 s for wild-
type and 2.81 s for S463A mutant CRN2 (Fig. S7, right graphs).
Figure 7 | Phosphorylation of S463 controls F-actin bundling activity and Arp2/3 interaction of CRN2. (A) two-step F-actin spin-down assay
employing rabbit skeletal muscle G-actin, bovine Arp2/3 complex and purified recombinant CRN2 wild-type (W), phosphomimetic S463D (D), and
S463A (A) mutant C-terminal fragments. Coomassie brilliant blue stained SDS-PAGE gels are shown. The left panel (10,000xg first pellet) demonstrates
F-actin bundling activity of wild-type and S463A mutant CRN2 in comparison to reduced bundling activity of S463D mutant CRN2. Vice versa the
middle panel (100,000xg second pellet) shows increased co-sedimentation of S463D mutant CRN2. Arp2/3 does not influence the results. Right panel,
100,000xg supernatant given as control. As further control, intensities of actin bands were analyzed by densitometry and themeasurements demonstrated
equal sums for the six triplets n1n’1n’’. (B) Arp2/3 immunoblot of a 100,000xg F-actin spin-down experiment. Presence of all CRN2 polypeptides
releases Arp2/3 from F-actin into the supernatant. This experiment only allows a qualitative assessment due to difficulties to completely dissolve the
pellets in SDS sample buffer and transfer the proteins onto the blot membrane88. (C) pull-down assay employing purified recombinant His-tagged CRN2
wild-type as well as S463A and phosphomimetic S463D mutant C-terminal polypeptides coupled to Ni-beads and soluble purified Arp2/3 complex.
In comparison to wild-type and S463A mutant CRN2, the S463D mutant shows reduced direct binding to Arp2/3. Arp2/3, p34 immunoblot;
CRN2pep, mAb K6-444 immunoblot. Beads, Ni-sepharose beads lacking CRN2; flow-through, Arp2/3 flow-through from these blank beads. (D) co-
immunoprecipitations using GFP mAb K3-167-26 coupled to Protein G coated beads and lysates from 293TN cells expressing GFP-tagged full-length
wild-type CRN2 as well as S463D and S463Amutants. Immunoblotting was performed with CRN2mAb K6-444 and p34 pAb (Upstate #07-227). S463D
mutant GFP-CRN2 shows reduced interactionwith the Arp2/3 complex. Prior to preparation of the lysates cells were treatedwith latrunculin B to prevent
unspecific co-precipitation of proteins tied together via F-actin bridges. (E) bar chart, densitometry analysis of the Arp2/3 signal intensity from three
independent experiments, where GFP-CRN2 wild-type and S463D mutant were parallelly immunoprecipitated; one experiment is shown in D. Arp2/3
values are normalized to the respective GFP-CRN2 values.
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Discussion
We identified CRN2 as a novel direct binding partner and substrate
of CK2a. This interaction results in phosphorylation of S463 within
the coiled coil domain of CRN2. Although it has been shown that
CK2 phosphorylation sites in many proteins overlap with sites of
caspase cleavage46, this is not the case for S463 of CRN2, since this
residue is not part of the consensus motif of caspase 3. Instead, the
S463 phosphorylation inhibits the actin filament crosslinking activity
and the Arp2/3 binding capacity of CRN2.
Phosphorylation is a common mechanism to regulate coronin
protein activity. CRN1 (synonyms: coronin 1B, coronin 2) and
CRN4 (synonyms: coronin 1A, coronin 1) are substrates of protein
kinase C (PKC). In the case of CRN1 PKC phosphorylates serine 2, a
residue that is not present in CRN2, and thereby inhibits the inter-
action between Arp2/3 and CRN1. As a consequence, cell migration
velocity is reduced and the PMA-induced membrane ruffling is sup-
pressed47. For CRN4 the specific PKC phosphorylation site is
unknown. However, phosphorylation of CRN4 leads to its dissoci-
ation from phagosomes and a role of CRN4 in the maturation of
phagosomes has been postulated48.
Thus far, only three studies have reported a specific interaction of
CK2 with actin or actin-associated proteins in mammalian cells.
First, rabbit skeletal muscle G-actin directly binds to the CK2a sub-
unit and inhibits the activity of CK2 in a dose-dependent manner in
vitro49. More importantly, CK2 phosphorylates the VCA domain of
WASP at serine residues 483 and 484, which in turn enhances the
interaction of VCA domain with the Arp2/3 complex and thereby
increases the velocity of Arp2/3 mediated actin polymerization50.
Furthermore, CK2 synergizes with CKIP-1 to inhibit the actin cap-
ping protein CapZ at the barbed ends of actin filaments in actin
de-polymerization assays and actin polymerization assays starting
from spectrin-F-actin seeds, but neither protein has an influence on
the dissociation of CapZ from F-actin in uncapping assays51. In sum-
mary, CK2 is able to promote actin polymerization and reduce the
formation of crosslinked actin filaments (Fig. 10).
From our results we conclude that wild-type, S463D and S463A
mutant CRN2 polypeptides do not exert any capping effect, but most
likely bind to the side facing the actin filaments as described for
CRN452. However, only the direct binding of wild-type and S463A
mutant CRN2 polypeptides to F-actin leads to a reduced polymer-
ization velocity. All CRN2 polypeptides were able to partially
displace the Arp2/3 complex at actin filaments and, moreover,
wild-type and S463A mutant, but not the phosphomimetic S463D
CRN2 C-terminal polypeptides, were found to interact with free
Arp2/3 complex. Thus, the wild-type and S463Amutant CRN2 poly-
peptides may additionally inhibit actin polymerization in an indirect
manner (Fig. 10).
A competition of the Arp2/3 complex binding to F-actin has also
been reported for CRN1, which results in a reduced F-actin density in
the front of lamellipodia and a disturbed formation and persistence
of cell protrusions53. The exact binding site of the Arp2/3 complex on
CRN2 is unknown, but our pull-down and CoIP experiments
employing CRN2 polypeptides and full-length protein, respectively,
suggest that Arp2/3 binds to a motif in the coiled coil domain of
CRN2 harboring S463. For mammalian CRN4 and yeast CRN11
(synonym: Crn1p) the Arp2/3 binding site has also been mapped
to the coiled coil region3,54,55. CRN2 probably inactivates the Arp2/3
complex in a similar way as it has been described for CRN4, CRN1
and yeast CRN11, where coronin holds the Arp2/3 complex in an
inactive open conformation away from the actin filaments55,56,57,58.
Figure 8 | Expression of phosphomimetic S463D mutant CRN2 changes the F-actin network in the front of lamellipodia. Wild-type (not shown) as
well as S463A (A) and S463D (B) mutant GFP-CRN2 was expressed in U373 glioblastoma cells where the endogenous CRN2 was knocked down (95%
efficiency, shown in8). The CRN2 over-expression constructs are resistant to the CRN2 specific shRNA used for the knock-down (see Materials and
Methods). A,B, left three panels, double stainings of CRN2 (GFP-fluorescence) and actin (TRITC-phalloidin fluorescence). A,B, right three panels,
double stainings of CRN2 (GFP-fluorescence) and Arp2/3 (indirect immunofluorescence). Lamellipodia of cells expressing S463D mutant CRN2
demonstrate actin filaments within their fronts which were re-organized into irregular spiky structures in conjunction with irregularly distributed Arp2/3
complex (arrows) and a thinner region of CRN2 and Arp2/3 complex co-localization (distance labels). In contrast S463A induced regular patterns of F-
actin and Arp2/3 in the front of lamellipodia (arrowheads). The patterns observed for wild-type CRN2 expressing cells varied between the ones detected
for S463A and S463D CRN2 expressing cells and are not shown; see also Fig. S3.
www.nature.com/scientificreports
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Figure 9 | Phosphorylation of serine residue 463 controls protrusion formation and cell migration. (A) live cell imaging of formation and retraction of
cell protrusions. Single 293TN cells expressing wild-type, S463D or S463A mutant CRN2 were monitored. Expression of the S463D mutant led to a
distinct reduction (,50%) of the number of cellular protrusions. CRN2 wild-type vs. CRN2 S463Dmutant: mean no. of cellular protrusions 6.0 vs. 2.8,
standard deviation 2.1 vs. 2.2, 90 measurements each, Student’s t-test p5 4310219. (B) in vitro wound healing assays employing 293TN cells expressing
full-length wild-type, S463D or S463Amutant CRN2. Cells expressing the S463Dmutant show a small but statistically significant defect in wound closure
velocity. CRN2 wild-type vs. CRN2 S463D mutant: mean wound closure velocity 29 mm/h vs. 23 mm/h, standard deviation 8.6 mm/h vs. 7.5 mm/h,
60 measurements for each, Student’s t-test p 5 0.04. (C) GFP-fused CRN2 wild-type, S463D, or S463A was transiently expressed in primary human
macrophages. FRAP experiments were performed to determine protein turn-over rates and dissociation constants in F-actin-rich podosome cores (for
details see Fig. S7). Note the reduced turn-over rate of the S463D variant (lower koff value of 0.11 s
21; standard deviation 0.017 s21; Mann-Whitney test
wild-type vs. S463D mutant p 5 0.0036) compared to wild-type (0.31 s21; standard deviation 0.09 s21) and S463A mutant CRN2 (0.25 s21; standard
deviation 0,021 s21). Each bar represents mean value and standard deviation from 15 measurements from podosomes of at least 3 different cells.
www.nature.com/scientificreports
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Previous studies indicated that full-length CRN2 possesses bind-
ing sites for F-actin in the conserved WD40-repeat domain forming
the seven-bladed b-propeller6,59 and in the conserved part of the C-
terminal linker region3,4,59,60,61. More specifically, a conserved argi-
nine residue, R30 in CRN1 and R28 in CRN2, which is surface
exposed and located within the seventh b-propeller blade3, has
turned out to be essential for F-actin binding of both coronin pro-
teins12,62. A belt-shaped actin binding region on the surface of the b-
propeller has been identified in yeast CRN1163, which is conserved in
all coronin proteins. Moreover, for mammalian CRN4 a specific F-
actin binding motif was shown in the C-terminal linker region
(aa400-416)61, which is conserved in CRN2 (aa398–418, 59% sim-
ilarity, and 32% identity). Subsequent studies have demonstrated
that the residues of CRN4 that bind to actin span over the entire
molecule and specifically locate to the b-propeller and the C-ter-
minal linker region52,54. The corroborative data from all these reports
indicate that the scattered positions of actin binding sites in co-
ronin proteins map from the N-terminal part to the C-terminal
linker and form one large F-actin binding region which can make
contacts to several actin molecules. In this scenario one coronin
molecule apparentlymakes contacts to three actinmolecules, namely
between two actin molecules of one and an additional actin mole-
cule of the second ‘‘substrand’’ of the two-start helix of an actin
filament52,64.
Apart from this widespread actin binding region another actin
binding site has been detected in the coiled coil domain of CRN4
and yeast CRN1160,65. Our data show that CRN2 also contains an
additional actin binding site in the coiled coil domain. The C-ter-
minal CRN2 polypeptides used in our in vitro analyses were proven
to fold properly6 and comprise a part of this large belt-shaped actin
binding region as well as the coiled coil domain. Phosphorylation of
S463 within the coiled coil inactivated this second actin binding site
so that the actin filament crosslinking activity of CRN2 was reduced
but the F-actin binding activity retained. Thus, the second actin
binding site within the coiled coil domain of CRN2 is a CK2 depend-
ent regulatory element for actin filament crosslinking (Fig. 10).
Our data strongly suggest that the coiled coil domain of CRN2 has
three major functions, i) formation of a constitutively trimeric CRN2
quaternary structure, ii) binding to actin filaments, and iii) inter-
action with the Arp2/3 complex. However, only trimerization and
F-actin binding, or alternatively trimerization and Arp2/3 inter-
action of (non-phosphorylated) CRN2, can occur at the same time.
A simultaneous binding to F-actin and Arp2/3 apparently is not
possible as CRN2 was found to displace the Arp2/3 complex from
actin filaments. This agrees with results of the FRAP experiments in
this study, which show a 3.5-fold increased half-life time of the
phosphomimetic CRN2 S463D mutant in podosome F-actin cores.
As these cores are rich in Arp2/3 complex the S463D mutant CRN2
lacking the ability to interact with the Arp2/3 complex exhibited a
prolonged interaction with F-actin.
Based on our data we assume that in vivo the cellular fraction of
non-phosphorylated CRN2, previously described as cytoskeleton
associated pool4, inhibits actin polymerization, bundles actin fila-
ments, binds to and inactivates Arp2/3 complexes, and accordingly
leads to the formation of ‘stabilized’ F-actin structures (Fig. 10).
Phosphorylation of CRN2 by CK2 inhibits these CRN2 functions.
This is supported by our observations where the presence of S463D
phosphomimetic full-length CRN2 correlated with an accumulation
of F-actin structures and an irregular re-distribution of the Arp2/3
complex in the front of lamellipodia, a reduced velocity of cell migra-
tion, and a decreased number of cell protrusions.
Methods
Molecular modeling. The sequence of CRN2 aa315-474 was subjected to multimeric
coiled coil prediction by the program MultiCoil66, which predicted, in addition to
experimental evidence4, a trimeric coiled coil for the peptide sequence CRN2 aa438-
467 with a probability of 62%. While the three-dimensional crystal structure of the
coiled coil domain of CRN4 has been determined67, the amino acid sequence
alignment of the CRN4 and CRN2 coiled coil domains showed that CRN4 lacks a
hexapeptide in this region. We have therefore re-constructed the trimeric coiled coil
of hemagglutinin (HA2 chain) using residues 74 to 113 from chain B in PDB entry
1eo836, and used this as a template for comparative modeling. Twenty independent
models for CRN2 aa435-474 were generated withMODELLER68 and the one with the
Figure 10 | Scheme summarizing effects of CK2 and CRN2 on actin dynamics. CK2 phosphorylates CRN2 at S463; CRN2 constitutively forms trimers
independent of its phosphorylation state; CRN2 and phospho-CRN2 both bind to F-actin; CRN2 strongly inhibits actin polymerization, whereas
phospho-CRN2 is nearly inactive; CRN2 strongly and phospho-CRN2 to a much lesser extent bundles F-actin; CRN2, but not phospho-CRN2 interacts
with the Arp2/3 complex; both CRN2 and phospho-CRN2 compete with Arp2/3 for F-actin binding. Full-length CRN2 contains a large actin filament
binding region formed by the b-propeller and a second distinct actin filament binding site within the coiled coil domain. Arp2/3 mediated branching of
actin filaments is not included in this scheme. Data on the interactions of CK2 with VCA domain of WASP, and with CKIP-1 and CapZ were obtained
from other studies50,51 and embedded into this scheme. Taken together, a picture emerges where CK2 acts in an integrative manner and promotes actin
polymerization and suppresses actin filament bundling.
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lowest energy was selected. The overall geometry was scrutinized using
PROCHECK69.
Molecular cloning and protein expression.A human CRN2 cDNA fragment coding
for a C-terminal polypeptide cloned into the pQE30 (Qiagen) vector (aa300-4746,)
and a full-length CRN2 cDNA cloned into pEGFP-C1 (Invitrogen) vector (aa1-4744,)
were used as templates. Using the QuickChange Site-Directed Mutagenesis kit
(Stratagene) in conjunction with primer pairs i) CRN2mutS463Dfor 59-
GCAATCAAGATGAGCGTATTTCCAAGTTAGAACAGCAGATGGC-39 and
CRN2mutS463Drev 59-GCCATCTGCTGTTCTAACTTGTCAATACGCTCAT-
CTTGATTGC-39, ii) CRN2mutS463Afor 59-CAATCAAGATGAGCGT-
ATTGCCAAGTTAGAACAGCAGATGGC-39 and CRN2mutS463Arev 59-GCC-
ATCTGCTGTTCTAACTTGGCAATACGCTCATCTTGATTGC-39, and iii)
CRN2shRNA77resistFor 59-GAATCCCCGTACGTGCACTATCTCAATACA-
TTTAGCAGCAAG-39 and CRN2shRNA77resistRev 59-CTTGCTGCTAAA-
TGTATTGAGATAGTGCACGTACGGGGATTC-39 the following expression
constructs were generated and verified by sequencing: pQE30-CRN2-S463D, pQE30-
CRN2-S463A, pEGFP-CRN2-S463D, pEGFP-CRN2-S463A, pEGFP-CRN2res-WT,
pEGFP-CRN2res-S463D, and pEGFP-CRN2res-S463A. The ‘CRN2res’ expression
constructs were used for transfections of cells in which a stable expression of the
CRN2 specific shRNA oligo cgtccactacctcaacacatt led to a 95% reduction of the
endogenous CRN2 levels8. Expression and purification of CRN2WT, S463D, S463A
C-terminal polypeptides from M15 E. coli cells was carried out according to4.
Full-length human GST-His6-tagged CRN2 wild-type and S463Dmutant proteins
were purified from Sf9 insect cell cultures according to the manufacturer’s protocol
(bac-to-bac expression system, Invitrogen). In brief, the DH10Bac E. coli strain was
transformed with a pDEST10 donor vector containing a GST-His6-CRN2 cassette
and subsequently used for the purification of recombinant bacmid DNA. The latter
was used to transfect Sf9 cells and resulting baculoviruses were amplified several times
in order to finally infect Sf9 cells cultivated in spinner flasks (Techne) using Sf-900 III
SFM medium (Invitrogen).
pGEX-2T based vectors for expression of GST-tagged chicken CK2a and CK2a
kinase dead (K68A mutant) were kindly provided by Drs. Odile Filhol-Cochet
(iRTSV - CEA, Grenoble, France) and Yves Goldberg (University Joseph Fourier,
Grenoble, France), and purified as described earlier70,71. Identity of all purified pro-
teins was confirmed by mass spectrometry.
Mammalian cell culture and life cell imaging. HEK293 human embryonic kidney
(ATCC: CRL-1573), 293TN human pseudoviral particle producer (BioCat/SBI:
LV900A-1), U373 human glioblastoma (ECACC: 89081403), and Pop10 human
hepatocarcinoma72 cells were grown in Dulbecco’s modified Eagle’s Medium
(DMEM, 4.5 g/l glucose, Sigma) supplemented with 10% fetal calf serum (Biochrom),
1 mM sodium pyruvate, 0.1 mM non-essential amino acids, 2 mM L-glutamine
(Sigma), 100 units/ml penicillin G, and 100 mg/ml streptomycin (Invitrogen). Cells
were grown in 5%CO2 at 37uC. For transfections of HEK293, 293TN, and Pop10 cells
at 50–80% confluence the lipofectamine 2000 reagent (Invitrogen) and for
electroporation of U373 cells the Nucleofector II device (Amaxa/Lonza) were used.
Generation of U373 cells stably expressing the CRN2 specific shRNA oligo
cgtccactacctcaacacatt is described in8. In vitro wound healing and single cell
protrusion assays were performed according to6. Primary human macrophages were
generated as described in73. Macrophages were transiently transfected using a
MicroPoratorMP-100 electroporation device (PeqLab) by applying two pulses with a
pulse voltage of 1000 V and pulse width of 40 ms and subsequently seeded on cover-
slips or glass-bottom cell culture dishes.
Gel filtration analyses. Purified CRN2 C-terminal polypeptides expressed in E. coli,
purified GST-tagged or GST-cleaved full-length CRN2 expressed in insect cells, and
GFP-tagged CRN2 expressed in mammalian cells were used for gel filtration assays.
Purified polypeptides and proteins or the cell lysates were pre-cleared at 100,000xg for
60 min, injected into Superdex G-75 or G-200 columns, and analyzed using the
SMART system (Amersham Biosciences). 50-ml fractions collected at the end of each
run were analyzed by immunoblotting.
The phosphorylated CRN2 coiled coil aa435-474 with pS463 was obtained as
synthetic peptide from Metabion, Germany, and subjected to gel filtration analyses
with multi-angle light scattering detection (SEC-MALS) after separation by a
Superose-12 column. The samples had concentrations of 4.5, 9 and 18 mg/ml, and the
buffer conditions were 20 mM HEPES (pH 7.5) and 100 mM NaCl (normal salt) or
500 mM NaCl (high salt). The SEC-MALS combination consisted of a BioRad
DuoFlowHPLC coupled to aWyatt miniDawn TREOS light scattering detector and a
Shimadzu RID-10A refractive index detector. MALS analysis was carried out using
the Wyatt ASTRA software.
Small-angle X-ray scattering. Small-angle X-ray scattering data of the sythetic CRN2
coiled coil peptide (435–474) was acquired on a SAXSess instrument (Anton Paar,
Austria) with a sealed tube microsource (Cu-Ka). Data collection was performed by
multiple 10 s exposures at 20uC in re-usable thermostated quartz capillaries, which
were placed in the integrated vacuum chamber of the camera. Datasets were recorded
on a CCD detector and software CCDquant, covering a momentum transfer range of
0.003 , q , 2.8 A˚21, where q 5 (4psinh)/l, 2h is the scattering angle, and l is the
radiation wavelength. The measured data were corrected for dark current,
background scattering from 100 mM NaCl, 20 mM Hepes (pH 7.5) was subtracted,
and the data were de-smeared using the instrument-specific profile (SAXSquant). A
water sample was used as calibration standard. Data were recorded at r*, r*/2 and
r*/4, with r* 5 18 mg ml21.
The radius of gyration Rg and the intensity of forward scattering I(0) were deter-
mined by Guinier analysis using PRIMUS74. Both parameters were also determined
together with the distance distribution function p(r) by the program GNOM75. The
experimental molecular mass was calculated from the intensity of forward scattering
I(0) using the formula: M 5 I(0)3NA3r*213Dr22; Dr 5 231010 cm g21; NA 5
6.02231023 mol21, where Dr is the excess scattering length per unit mass of the
protein and NA is Avogadro’s number.
Ab initiomodels of the scattering particles were obtained by shape restoration with
DAMMIN76. For each dataset, twenty independent models were generated and
averaged using DAMAVER andDAMFILT76. The final shape obtained for dataset r*
5 18 mgml21 was used to fit the atomicmodel of the triple phosphorylated coiled coil
peptide from the MD simulation (see above). Model fitting was performed with the
program SAFIR from the PCSB collection77; theoretical scattering curves and their fit
to experimental data were obtained with CRYSOL39.
GST pull-down analyses. Cell extracts were prepared by lysing HEK293 cells with
buffer A (10 mMHEPES pH 7.9, 10 mM KCl, 0.1 mM EDTA, 1 mMDTT, 0.5 mM
PMSF, 0.5% NP40) and E. coli cells with buffer B (200 mM NaCl, 5% glycerine, 100
mg/ml lysozyme, 0.5% NP40, 10 mM DTT, 0.5 mM PMSF, 2 mM Benzamidin, 10
mg/ml aprotinin and leupeptin) on ice followed by sonication. Clarified soluble
extracts were obtained by centrifugation at 100,000xg for 5 min at 4uC. In parallel,
GST-CK2a fusion proteins purified from bacteria were mixed with 100 ml of
equilibrated glutathione sepharose beads (GE Healthcare) and incubated for 2 h at
4uC. After 4 washes with buffer C (4.3 mM NaH2PO4, 1.47 mM KH2PO4, 1.37 mM
NaCl, 2.7 mM KCl), aliquots of the beads were incubated together with the
supernatants from either HEK293 cells expressing GFP-tagged CRN2 proteins or
bacteria containing His6-tagged CRN2 C-terminal polypeptides. Further incubation
for 2 h at 4uCwas carried out to pull-down respective proteins. Finally, the beads were
washed 3 times with wash buffer D (4.3 mMNaH2PO4, 1.47 mMKH2PO4, 1.37 mM
NaCl, 2.7 mM KCl, 5% glycerin), and proteins were eluted with SDS sample buffer
and analyzed by immunoblotting. Control experiments were performed with GST-
coated beads or soluble GFP protein alone.
In vitro kinase assays. In vitro CK2a kinase assays were performed in
phosphorylation buffer (50 mMMOPS pH 7.0, 150 mMNaCl, 10 mMMgCl2, ATP
and [c-32P]ATP (10 mCi/ml, Amersham)) according to78. His6-tagged CRN2 C-
terminal polypeptides (,4 mg) as well as full-length GST-tagged CRN2 (,0.2 mg)
proteins were added to 50 ml of 2x phosphorylation buffer without [c-32P]ATP. The
reaction was initiated by addition of CK2a (,0.2 mg) with the final addition of 5 ml
ATPmix (6 ml 2 mMATP, 2.4 ml 10 mCi/ml [c-32P]ATP, 51.6 ml H2O). After adjusting
the reaction volume to 100 ml, the reactionmixtures were incubated for 1, 5, 10, 30, 60,
90, and 120 min at 30uC. The reactions were terminated by addition of 20 ml 60 mM
EDTA, 30 ml 5x SDS sample buffer, and boiling for 10 min at 95uC. All samples were
analyzed by SDS-PAGE followed by Coomassie brilliant blue staining and
autoradiography.
In vitro de-phosphorylation assays and 2D gel electrophoresis. Alkaline
phosphatase is able to hydrolyze phosphate esters of primary and secondary alcohols,
amines, and phenols, including serine, threonine and tyrosine residues in proteins.
For in vitro de-phosphorylation 20 mg of murine skeletal muscle tissue was
pulverized on dry ice, dissolved in de-phosphorylation buffer (100 mM Tris/HCl pH
7.9, 100 mM NaCl, 10 mM MgCl2, 1 mM DTT, 15200 protease inhibitor (Sigma)),
and centrifuged for 10 min at 16,000xg. 5 ml (5 U) alkaline phosphatase (Roche) were
added to the supernatant and incubated for 30 min at 30uC. Positive controls
additionally contained p-nitrophenylphosphate (pNPP), negative controls lacked the
phosphatase. Samples were subjected to two-dimensional gel electrophoresis in
conjunction with immunoblotting according to79. CRN2 protein spots were
visualized with enhanced chemiluminescence followed by exposure to x-ray films
(Kodak).
In vivo kinase assays.Day 0: 293TN cells were seeded into 10 cm culture dishes. Day
1: Three dishes with a cell confluence of 30% were selected for lipofectamine 2000
transfections with the EGFP-CRN2-WT construct. Day 3: The growth medium was
replaced by 10 ml phosphate-free DMEM (Gibco 11971) supplemented with 10%
fetal calf serum (Biochrom), 1 mM sodium pyruvate, 0.1 mM non-essential amino
acids, 2 mM L-glutamine (Sigma), 100 units/ml penicillin G, and 100 mg/ml
streptomycin (Invitrogen). After 2 hours of incubation the medium was exchanged
for 4 ml of the above phosphate-free medium without fetal calf serum (serum may
attenuate or inhibit the efficiency of TBB). Either 40 ml of DMSO (control), CK2
inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB; final concentration 100 mM; 10 mM
stock inDMSO)80,81,82, or CK2 activator 1-ethyl-4,5-dicarbamoylimidazole41,42,43 (final
concentration 20 nM; 20 mM stock in H2O) and DMSO were added to the three
culture dishes. After 2 hours of pre-incubation with the drugs 1.25 mCi (230 ml) 32P-
orthophosphate (PerkinElmer, NEX053) were added to each dish. Day 4: Cells were
harvested, washed three times with phosphate- and serum-freemedium, lysed in 1 ml
lysis buffer (50 mM Tris/HCl pH 8.0, 150 mMNaCl, 1% Triton X-100), centrifuged,
and GFP-CRN2 was immunoprecipitated from the 16,000xg supernatant using 50 ml
Anti-GFP-tag MicroBeads (Miltenyi Biotec). Beads were collected in M-columns
(void volume 80 ml) and washed twice with 600 ml lysis buffer, three times with wash
buffer 1 (50 mM Tris/HCl pH 8.0, 150 mM NaCl, 0.1% Triton X-100), three times
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with wash buffer 2 (50 mM Tris/HCl pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% Na-
deoxycholate, 0.1% SDS), and finally once with buffer 3 (20 mM Tris/HCl pH 7.5).
The lysis buffer contained phosphatase (Sigma) and protease (Roche) inhibitor
cocktails in double concentration. Immunoprecipitated GFP-CRN2 was eluted with
70 ml elution buffer (50 mM Tris/HCl pH 6.8, 50 mM DTT, 1% SDS, 1 mM EDTA,
10% glycerol, 0.005% bromphenol blue), subjected to SDS-PAGE, Coomassie
brilliant blue staining, and autoradiography. A duplicate set of three plates was treated
in parallel in order to harvest cells for immunoblotting. The duplicates were not
incubated with32P-orthophosphate but with medium containing phosphate at the
appropriate steps of the experiment.
Actin polymerization assays.Actin polymerization assays were performed using the
Actin polymerization Biochem kit (BK003, Cytoskeleton) in which the rate of pyrene-
labelled G-actin conversion into F-actin was monitored. Pyrene fluorescence signals
were monitored in black flat bottom 96 well plates (Nunc) using an Infinite M1000
device (Tecan) equipped with Tecan i-control (version 1.6.19.2) with the following
settings: all samples and device equilibrated to 25uC, fluorescence top reading,
excitation 350 nmwith 20 nm bandwidth, emission 407 nmwith 20 nm bandwidth,
gain 85, 20 flashes at 400 Hz, 20 ms integration time, 200 ms settle time, 20198 mmZ-
position, 30 s measurement interval, polymerization start by dispension of 13 ml 10x
polymerization buffer (500 mMKCl, 20 mMMgCl2, 10 mMATP), final volume per
well 125 ml. Pyrene-labelled rabbit skeletal muscle G-actin, bovine brain Arp2/3
complex (RP01, Cytoskeleton), recombinant human GST-tagged VCA-domain of
WASP (VCG03, Cytoskeleton), and His6-tagged CRN2 C-terminal polypeptides
were prepared in G-buffer (5 mM Tris-HCl pH 8.0, 0.2 mM CaCl2). Final
concentrations were: G-actin 1.5 mM (Fig. 6A,B,E) or 2 mM (Fig. 6C,D), Arp2/3
complex 37 nM in conjunction with VCA-domain 19 nM, CRN2 polypeptides 3 mM
(Fig. 6A,E), 0.75 mM (Fig. 6B), 0.5 to 5 mM (Fig. 6C), 0.5 and 2.5 mM (Fig. 6D). Several
different experiments were conducted for all combinations of proteins. To exclude a
potential quenching effect of the CRN2polypeptides, identical volumes of G-buffer or
CRN2 polypeptides were added to separate wells after polymerization of actin. In
order to verify the amounts of the CRN2 polypeptides added to the reactions, samples
from all wells were taken at the end of each experiment, separated by SDS-PAGE, and
proteins were stained by Coomassie brilliant blue.
G-actin binding assays. Three-dimensional fluorescence spectrometry was
employed to investigate a potential interaction of CRN2 and G-actin. Changes of the
fluorescence signals of pyrene-labelled G-actin upon addition of identical amounts of
the CRN2 C-terminal polypeptides were monitored using the Infinite M1000 device
(Tecan) with the following settings: all samples and device equilibrated to 25uC,
fluorescence top reading, excitation start 310 nm, excitation end 364 nm, excitation
step size 2 nm, excitation bandwidth 5 nm, emission start 372 nm, emission end
444 nm, emission step size 2 nm, emission bandwidth 5 nm, gain 100, 20 flashes at
400 Hz, 20 ms integration time, 20198 mmZ-position, volume per well 125 ml. Pyrene-
labelled rabbit skeletal muscle G-actin, His6-tagged CRN2 C-terminal polypeptides,
BSA (present in all assays), a WH2 domain from CAP2 (positive control for G-actin
interaction generously provided byDr. Vivek Peche) were prepared in G-buffer. Final
concentrations were: G-actin 2 mM, CRN2 polypeptides, BSA, and CAP2WH 2 mM.
Negative controls lacked the CRN2 C-terminal polypeptides or both, CRN2
polypeptides and the BSA. All assays were also carried out in absence of pyrene-
labelled G-actin to determine the intrinsic fluorescence of the CRN2 C-terminal
polypeptides.
Actin spin-down assays. 75 ml samples derived from the actin polymerization assays
were used for sequential low (10,000xg) and high speed (100,000xg) centrifugation
steps in order to investigate the actin binding and bundling activity, respectively, of
the CRN2 C-terminal polypeptides according to83. Equal amounts of the two pellets
and the final supernatant were resolved by SDS-PAGE and proteins were visualized
byCoomassie brilliant blue staining. Controls contained only theCRN2 polypeptides.
Another 25 ml samples derived from the polymerization assays were separated into
100,000xg supernatant and pellet to determine the competitive influence of the CNR2
C-terminal polypeptides on the F-actin – Arp2/3 interaction according to84. Pellets
and supernatants were resolved by SDS-PAGE and analyzed by immunoblotting.
Arp2/3 pull-down assays. Equal amounts of His6-tagged CRN2 C-terminal
polypeptides were incubated with 50 ml of Anti-His-tagMicroBeads (Miltenyi Biotec)
in 250 ml lysis buffer (50 mM Tris/HCl pH 8.0, 150 mMNaCl, 1% Triton-X-100) for
1 h on ice. Incubation was further prolonged for 1 h with addition of 2 mg bovine
Arp2/3 complex (RP01, Cytoskeleton). The mixture was passed through m-columns
(void volume 30 ml) prepared according to the manufacturer’s instructions. After
rinsing the columns with 4x 200 ml of wash buffer 1 (50 mM Tris/HCl pH 8.0,
150 mM NaCl, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS,) and 1x 100 ml of
wash buffer 2 (20 mM Tris/HCl pH 7.5), proteins were eluted with 120 ml of pre-
heated elution buffer (50 mMTris/HCl pH 6.8, 50 mMDTT, 1% SDS, 1 mMEDTA,
0.005% bromphenol blue, 10% glycerol) and analyzed by SDS-PAGE in conjunction
with immunoblotting.
Co-immunoprecipitation experiments. HEK293 cells transfected with pEGFP-
CRN2-WT, pEGFP-CRN2-S463D, or pEGFP-CRN2-S463A were treated with
latrunculin B according to6, harvested and lysed on ice with immunoprecipitation
(IP) buffer (20 mMHEPES pH 7.0, 100 mM KCl, 0.5% NP-40, 1 mM EDTA, 1 mM
PMSF, 10 mg/ml 1,10-pheanthroline, 10 mg/ml aprotinin, 10 mg/ml leupeptin, 10 mM
NaF, 2 mM sodium orthovanadate) followed by sonication. The lysates were cleared
at 13,000xg for 5 min and incubated for 2 h with 500 ml of concentrated GFP mAb
K3-167-26. Protein G coated sepharose beads (Zymed) were washed extensively with
IP buffer, pre-blocked with 5% BSA, added to the cell lysates and further incubated
overnight. Collected immune complexes were washed several times with IP buffer
before the beads were boiled in SDS sample buffer. Proteins were separated by SDS
PAGE and analyzed by immunoblotting.
Immunofluorescence analyses, immunoblotting, and antibodies. Direct and
indirect immunofluorescence analyses as well as immunoblotting were performed as
described in85. Immunofluorescence images were captured on a Leica TCS SP5/
AOBS/tandem scanning system equipped with the Leica LAS-AF software (version
2.2.1 build 4842) and further processed using CorelDraw Graphics Suite X4.
Visualization of immunoblots was done by enhanced chemiluminescence in
conjunction with the imaging system Fluorchem SP (Alpha Innotech) or exposure to
x-ray films (Kodak). Antibodies used in this study specifically recognized CRN2
(mAbK6-444-44,), Arp2/3 complex (p34-Arc subunit, rabbit polyclonal Ab, Upstate),
GST (rabbit polyclonal antibody86,), CK2a (mAb 1AD9, KinaseDetect), and cdc37
phosphorylated at serine 13 (45; note, that the rabbit polyclonal Ab ab61797 (Abcam)
also recognizes non-phosphorylated cdc37); F-actin was labelled with 200 ng/ml
TRITC-phalloidin (Sigma).
Fluorescence recovery after photobleaching (FRAP) experiments. Transfected
primary human macrophages grown in glass-bottom culture dishes were placed in a
heating insert P covered with a small incubator S-2 for warm air incubation and CO2-
control (Pecon) mounted on a Leica TCS SP2 confocal microscope. Living cells were
kept at 37uC in a humidified atmosphere with 5% CO2 and observed using an oil
immersion HCX PL APO 63x/1.4-0.6 lambda blue objective lens. Subcellular
localization of GFP-tagged proteins was monitored using the 488 nm laser line of an
argon ion laser. Photobleaching experiments were performed as follows: before the
bleaching event 10–15 frames were acquired, then, by illumination of a selected
region with 100% laser light intensity using 10 bleaching iterations, GFP fluorescence
has been diminished. The recovery of fluorescence was recorded over time as
indicated. FRAP movies were analyzed by using Leica LCS Lite software (version
2.61) for the measurement of fluorescence signal intensities in defined regions of
interest (photobleached podosomes, background, control). Obtained raw data were
corrected for background fluorescence and acquisition photobleaching, normalized,
and further processed using Excel 2004 for Mac (Microsoft) and Systat SigmaPlot
(version 10) in order to calculate recovery and regression curves as described in87.
Podosome re-formation experiments. Transfected macrophages expressing mRFP-
Lifeact and GFP-CRN2 constructs were seeded on coverslips and cultivated for 6 h in
complete culture medium containing RPMI1640, 20% human serum, and penicillin/
streptomycin. Cells were then washed twice with plain RPMI1640 medium and
cultivated in basal medium overnight. The next day, control cells were fixed with 3.7%
formaldehyde directly before application of the Src family kinase inhibitor PP2 (4-
Amino-5-(4-chlorophenyl)-7-(t-Butyl)pyrozolo[3-4-d]pyrimidine; Calbiochem). To
monitor the re-formation of podosomes, the culture medium was replaced by 25 mM
PP2 in plain RPMI1640. After 30 min almost all macrophage podosomes were
disassembled, although cells were still adherent. Then, the inhibitor was washed out
with plain RPMI1640 and the cells were again incubated in full culture medium in
order to stimulate re-formation of podosomes. Macrophages were fixed after 45 min
for the analysis of GFP-CRN2 re-incorporation into podosomes using a Zeiss
Axiovert 200 M fluorescence microscope equipped with an EC Plan-Neofluar 40x/
0.75 objective. In several fields of view the total number of cells expressing GFP-CRN2
proteins were counted and correlated with the number of cells showing a clear co-
localization of GFP-CRN2 constructs withmRFP-Lifeact at podosomes. Graphs were
generated using Excel 2004 for Mac (Microsoft) and Prism 5.0c for Mac (GraphPad).
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